1-3 of 3
A. Hochhaus, MD
Close
Sort by
Journal Articles

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).

Hagop M. Kantarjian, MD, O. Ottman, MD, Jorge Cortes, MD, M. Wassman, MD, L. Wunderle, MD, K. Bhalla, MD, D. Jones, MD, A. Hochhaus, MD, P. Rae, L. Alland, MD, M. Dugan, MD, M. Albitar, MD, Francis Giles, MD
Journal: Blood
Blood (2005) 106 (11): 37.
https://doi.org/10.1182/blood.V106.11.37.37
Published: 2005
Journal Articles

Molecular Long-Term Surveillance of CML Patients on Imatinib Therapy. Follow-Up of German Patients Treated within the IRIS Trial.

Martin C. Mueller, MD, P. Paschka, MD, T. Lahaye, MD, Ch. Lorentz, MD, N. Gattermann, MD, D. Niederwieser, MD, G. Ehninger, MD, St Fruehauf, MD, A. Neubauer, MD, Th. Fischer, MD, B. Schultheis, MD, S. Kreil, MD, U. Haus, PhD, R. Hehlmann, MD, A. Hochhaus, MD, the German CML Study Group
Journal: Blood
Blood (2004) 104 (11): 1003.
https://doi.org/10.1182/blood.V104.11.1003.1003
Published: 2004
Journal Articles

Durable Molecular Remissions in Patients with Relapsed CML Post Allogeneic Stem Cell Transplantation upon Treatment with Imatinib-Mesylate (Glivec®, STI-571). Follow-Up Results of a Phase II Open-Label Study.

G. Hess, MD, D. Bunjes, MD, W. Siegert, MD, R. Schwerdtfeger, MD, G. Ledderose, MD, B. Waßmann, MD, G. Kobbe, MD, M. Bornhäuser, MD, A. Hochhaus, MD, A. J. Ullmann, MD, T. Kindler, MD, H. Geschaidmeier, PhD, C. Huber11, MD, T. Fischer12, MD
Journal: Blood
Blood (2004) 104 (11): 1004.
https://doi.org/10.1182/blood.V104.11.1004.1004
Published: 2004